Dexmedetomidine hydrochloride for stress disorders, post-traumatic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Apr 2025: Trial registered, NCT06943404
  2. 23 Feb 2026: Trial started, NCT06943404

The trials

NCT06943404: BXCL501 After Stress to Increase Recovery Success

State
Under way
Phase
Phase 2
People
100 planned
Started
23 Feb 2026
Primary completion
29 Sep 2026
Arms
BXCL501 (dexmedetomidine HCl)
Results
None posted
  1. 24 Apr 2025: Trial registered
  2. 23 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as BXCL501 (dexmedetomidine HCl), Cepedex, Dexdor, Dexmedetomidine Sublingual, Igalmi, Precedex, Sedadex, Sileo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.